



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Zoladex

Page: 1 of 4

Effective Date: 9/14/2023

Last Review Date: 7/7/2023

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input checked="" type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Zoladex under the patient's prescription drug benefit.

Description:

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. Prostate cancer
 - a. For use in combination with flutamide for the management of locally confined stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with Zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.
 - b. In the palliative treatment of advanced carcinoma of the prostate.
2. Endometriosis
For the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with Zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months. (Zoladex 3.6 mg strength only)
3. Endometrial thinning
For use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding. (Zoladex 3.6 mg strength only)
4. Advanced breast cancer
For use in the palliative treatment of advanced breast cancer in pre-and perimenopausal women.

B. Compendial Uses

1. Breast cancer
2. Prostate cancer
3. Preservation of ovarian function
4. Prevention of recurrent menstrual related attacks in acute porphyria
5. Uterine leiomyomata (fibroids)
6. Treatment of chronic anovulatory uterine bleeding with severe anemia



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Zoladex

Page: 2 of 4

Effective Date: 9/14/2023

Last Review Date: 7/7/2023

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input checked="" type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Zoladex

Policy/Guideline:

Exclusions:

Coverage will not be provided for members with any of the following exclusions: Use of the 10.8 mg strength for diagnoses other than prostate cancer and breast cancer.

Documentation:

Submission of the following information is necessary to initiate the prior authorization review: Hormone receptor status testing results (where applicable).

Criteria for Initial Approval:

A. Breast Cancer

Authorization of 12 months may be granted for the treatment of hormone receptor-positive breast cancer.

B. Prostate Cancer

Authorization of 12 months may be granted for treatment of prostate cancer.

C. Endometriosis

Authorization of a total of 6 months may be granted to members for treatment of endometriosis.

D. Endometrial-thinning agent

1. Authorization of 2 doses may be granted for endometrial thinning prior to endometrial ablation or resection for dysfunctional uterine bleeding.
2. Authorization of a total of 6 months may be granted for treatment of chronic anovulatory uterine bleeding with severe anemia.

E. Preservation of ovarian function

Authorization of 3 months may be granted for preservation of ovarian function when the member is premenopausal and undergoing chemotherapy.

F. Prevention of recurrent menstrual related attacks in acute porphyria



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Zoladex

Page: 3 of 4

Effective Date: 9/14/2023

Last Review Date: 7/7/2023

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input checked="" type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

Authorization of 12 months may be granted for prevention of recurrent menstrual related attacks in members with acute porphyria when the requested medication is prescribed by or in consultation with a physician experienced in the management of porphyrias.

G. Uterine leiomyomata (fibroids)

Authorization of a total of 3 months may be granted for treatment of uterine leiomyomata (fibroids) prior to surgery.

Continuation of Therapy:

A. Breast cancer

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization who are experiencing clinical benefit to therapy and who have not experienced an unacceptable toxicity.

B. Prostate cancer

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization who are experiencing clinical benefit to therapy (e.g., serum testosterone less than 50 ng/dL) and who have not experienced an unacceptable toxicity.

C. All members (including new members) requesting authorization for continuation of therapy for the specified indications below must meet all initial authorization criteria:

1. Endometriosis
2. Endometrial-thinning agent
3. Preservation of ovarian function
4. Prevention of recurrent menstrual related attacks in acute porphyria
5. Uterine leiomyomata (fibroids)

Approval Duration and Quantity Restrictions:

Approval:

- Endometriosis: 6 months
- Endometrial-thinning agent:
 - 2 doses for endometrial thinning prior to endometrial ablation or resection for dysfunctional uterine bleeding



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Zoladex

Page: 4 of 4

Effective Date: 9/14/2023

Last Review Date: 7/7/2023

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input checked="" type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

- Total of 6 months for chronic anovulatory uterine bleeding with severe anemia
- Preservation of ovarian function and uterine leiomyomata (fibroids): 3 months
- All others: 12 months

References:

1. Zoladex 3.6mg [package insert]. Deerfield, IL: TerSera Therapeutics LLC; December 2020.
2. Zoladex 10.8mg [package insert]. Deerfield, IL: TerSera Therapeutics LLC; December 2020.
3. The NCCN Drugs & Biologics Compendium® © 2022 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed November 7, 2022.
4. DRUGDEX® System (electronic version). Micromedex Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: www.micromedexsolutions.com. Accessed November 7, 2022.
5. Noguchi S, Kim HJ, Jesena A, et al. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer. *Breast Cancer (Tokyo, Japan)*. 2016;23(5):771-779. doi:10.1007/s12282-015-0637-4.
6. Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med*. 2015;372:923-32. doi:10.1056/NEJMoa1413204.
7. Clowse MEB, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. *J Womens Health (Larchmt)*. 2009 Mar; 18(3): 311-319. doi:10.1089/jwh.2008.0857.
8. Oktay K, Harvey BE, et al: Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology* 36:1994-2003, 2018.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed October 31, 2022.
10. Stein P, Badminton M, Barth J, Rees D, Stewart MF; British and Irish Porphyria Network. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. *Ann Clin Biochem*. 2013 May;50(Pt 3):217-23.
11. Innala, E, Bäckström, T, Bixo, M, Andersson, C. Evaluation of gonadotrophin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. *Acta Obstet Gynecol Scand* 2010;89:95-100.